Please use this identifier to cite or link to this item:
Scopus Web of ScienceĀ® Altmetric
Type: Journal article
Title: COX-2 inhibition and thrombotic tendency: a need for surveillance
Author: Cleland, L.
James, M.
Stamp, L.
Penglis, P.
Citation: Medical Journal of Australia, 2001; 175(20 August 2001):214-217
Publisher: Australasian Med Publ Co Ltd
Issue Date: 2001
ISSN: 0025-729X
Statement of
Cleland, L G ; James, M J ; Stamp, L K ; Penglis, P S
Abstract: Cyclooxygenase-2 (COX-2) inhibitors belong to a new class of drugs which have anti-inflammatory efficacy similar to that of traditional non-steroidal anti-inflammatory drugs (NSAIDs), but are associated with a reduced incidence of adverse upper gastrointestinal events. Biochemical evidence that COX-2 inhibitors could promote or exacerbate a tendency to thrombosis is supported by recent results from clinical trials and case reports. Two agents in this class, celecoxib and rofecoxib, have been listed on the Pharmaceutical Benefits Scheme (PBS) for very broad indications in chronic arthropathies, suggesting that they will move into widespread community use. It is important to canvass the possibility that use of these agents could be associated with thrombotic events.
Keywords: Humans
Arthritis, Rheumatoid
Gastrointestinal Diseases
Venous Thrombosis
Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase Inhibitors
Risk Factors
Middle Aged
Randomized Controlled Trials as Topic
DOI: 10.5694/j.1326-5377.2001.tb143099.x
Published version:
Appears in Collections:Aurora harvest
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.